Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NephrosNEPH +0.23%67 Debt-to-EBITDA is 0.18 as of Jun. 2026. GuruFocus rates NEPH with a GF Score™ of 67/100 and a GF Value™ of $2.97 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Nephros ranks better than 71.61% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Nephros's Debt-to-EBITDA or its related term are showing as below:
NEPH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.35 Med: -0.46 Max: 6.22
Current: 0.48
During the past 13 years, the highest Debt-to-EBITDA Ratio of Nephros was 6.22. The lowest was -1.35. And the median was -0.46.
NEPH's Debt-to-EBITDA is ranked better than 71.61% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs NEPH: 0.48
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nephros Debt-to-EBITDA Related Terms
Nephros Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Nephros's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NEPH vs MLSS, POCI, HBIO: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Nephros's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nephros Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nephros's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Nephros (NEPH) has a Debt-to-EBITDA of 0.18 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nephros. According to the industry distribution chart, Nephros ranks #134 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 28.4%.
Is Nephros' Debt-to-EBITDA too high?
Nephros' current Debt-to-EBITDA is 0.18. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. Nephros' value of 0.18 is 89% below this industry median. Based on the distribution chart, Nephros ranks #134 out of 472 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nephros has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nephros' Debt-to-EBITDA compare to MLSS and POCI?
According to the Medical Devices & Instruments industry distribution chart, Nephros ranks #134 out of 472 companies for Debt-to-EBITDA. This puts Nephros in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. Nephros' value of 0.18 is 89% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nephros's current Debt-to-EBITDA of 0.18 is 89% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nephros. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nephros's current Debt-to-EBITDA is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephros stock overvalued right now?
Based on GuruFocus' analysis, Nephros (NEPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.97, compared to a current price of $4.42 — trading 48.8% above its estimated fair value. The current Debt-to-EBITDA is 0.18 and 89% below the Medical Devices & Instruments industry median of 1.64. Nephros' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nephros (NEPH), the current Debt-to-EBITDA is 0.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nephros (NEPH) Overvalued in 2026?
Based on GuruFocus' analysis, Nephros stock appears to be overvalued.
The current stock price of $4.42 is trading 48.8% above its estimated GF Value™ of $2.97.
GuruFocus considers Nephros to be Significantly Overvalued.
Key valuation signals for NEPH:
Debt-to-EBITDA: 0.18
GF Value™: $2.97 vs. price of $4.42 (48.8% above fair value)
Industry Position: 89% below the Medical Devices & Instruments median (#134 of 472)
No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
67GF Score
Get the complete analysis for NEPH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEPH has been successfully added to your 
